Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Iradimed Notifies Potential Issue With Certain Syringe Adapter Sets During Use

Iradimed Corporation (NASDAQ:IRMD) notified a potential issue with some 1057 Syringe Adapter Sets related to the syringe venting function during use.…
byVandana Singh
February 27, 2023
1 minute read
Total
0
Shares
0
0
0
0
0
0
  • Iradimed Corporation (NASDAQ:IRMD) notified a potential issue with some 1057 Syringe Adapter Sets related to the syringe venting function during use.
  • The company designs, manufactures, markets, and distributes MRI-compatible medical devices, accessories, disposables, and related services.
  • The issue can lead to reduced flow with the MRidium infusion pump resulting in subsequent inlet occlusion and alarm indication. 
  • The 1057 Syringe Adapter Set is an IV fluid administration set with a vented syringe adapter (disposable tubing), which allows for the delivery of IV fluids from syringes while on the company’s infusion pump.
  • Also Read: Iradimed Withdraws FDA Application For Updated MR IV Pump System.
  • The customer notification, which outlines the potential risks associated with the 1057 Syringe Adapter Set, lists the affected products. 
  • The updated labeling provides specific actions users should take to identify any venting and infusion delivery issues before an unexpected inlet occlusion occurs.
  • Iradimed received five customer complaints of an unexpected inlet occlusion alarm resulting in the infusion being stopped, none of which were associated with injuries or death. 
  • Upon investigation, the company identified a defective injection molded part that can limit the effectiveness of the syringe vent and result in this condition in an estimated 0.4% of recently manufactured 1057 infusion sets.
  • No other of the company’s IV sets or disposables are involved, and the company does not expect any material financial impact from this action.
  • Price Action: IRMD shares closed higher by 0.16% at $37.48 on Friday.
 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Multi-Banner Cannabis Retailer’s Q3 Revenue Slumps Over 42% YoY But CEO Remains Optimistic

By Jelena Martinovic
January 3, 10:22 AM
Shiny Health & Wellness Corp. has reported a decrease in sales to CA$ 4.3 million ($3.2m million) for the three months ending October 31, 2023, down from CA$ 7.46m the previous financial year. The decline was attributed to market trends in the Ontario cannabis retail sector throughout the period, the pharmaceutical company said. Shiny Health also closed underperforming adult-use cannabis dispensaries and sold a number of larger stores. The Toronto-based firm recently inked an agreement with Karan S. Holla for his chain of 10 adult-use cannabis retail outlets, Stash & Co. CEO Meris Kott said Shiny Health was gradually building its brand presence in Ontario. The pharma company revealed that it made a CA$ 6m net loss for the quarter, an uptick from the CA$ 1.75m loss in the corresponding period the year before.

TSXV:SNYB